Core Viewpoint - The Ardent Health class action lawsuit alleges that the company and its executives made misleading statements regarding financial practices and liability reserves, leading to significant stock price declines following revelations of financial discrepancies [3][4]. Group 1: Allegations and Financial Impact - The lawsuit claims that Ardent Health did not accurately assess the collectability of accounts receivable, which inflated reported financial positions [3]. - On November 12, 2025, Ardent Health disclosed a $43 million decrease in third quarter 2025 revenue due to revised accounts receivable assessments, resulting in a nearly 34% drop in stock price [4]. - The company also cut its 2025 EBITDA guidance by approximately 9.6%, from a range of $575 million - $615 million to $530 million - $555 million, citing industry-wide cost pressures [4]. Group 2: Legal Process and Representation - Investors who purchased Ardent Health securities during the specified class period can seek to be appointed as lead plaintiff in the class action lawsuit [5]. - The lead plaintiff will represent the interests of all class members and can choose a law firm to litigate the case [5]. Group 3: Company Overview - Ardent Health operates a network of hospitals and clinics providing various healthcare services [2].

SAN DIEGO, Jan. 29, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Ardent Health, Inc. (NYSE: ARDT) securities between July 18, 2024 and November 12, 2025, inclusive (the "Class Period"), have until March 9, 2026 to seek appointment as lead plaintiff of the Ardent Health class action lawsuit. Captioned Postiwala v. Ardent Health, Inc., No. 26-cv-00022 (M.D. Tenn.), the Ardent Health class action lawsuit charges Ardent Health as well as certain of Ardent Healt ...

SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Ardent Health, Inc. (NYSE: ARDT) securities between July 18, 2024 and November 12, 2025, inclusive (the “Class Period”), have until March 9, 2026 to seek appointment as lead plaintiff of the Ardent Health class action lawsuit. Captioned Postiwala v. Ardent Health, Inc., No. 26-cv-00022 (M.D. Tenn.), the Ardent Health class action lawsuit charges Ardent Health as well as cer ...

Core Viewpoint - The Ardent Health class action lawsuit alleges that the company and its executives made misleading statements regarding financial practices and failed to disclose critical information about accounts receivable and liability reserves, leading to significant financial losses for investors during the specified class period [1][3][4]. Company Overview - Ardent Health, Inc. operates a network of hospitals and clinics providing various healthcare services [2]. Allegations of the Lawsuit - The lawsuit claims that Ardent Health did not rely on accurate methods for determining the collectability of accounts receivable, which allowed the company to report inflated figures [3]. - It is alleged that Ardent Health's accounts receivable framework utilized a 180-day cliff for reserving accounts, delaying the recognition of losses on uncollectible accounts [3]. - The lawsuit states that Ardent Health did not maintain sufficient professional malpractice liability insurance and that its reserves were inadequate to cover increasing social inflationary pressures in medical malpractice cases [3]. Financial Impact - On November 12, 2025, Ardent Health reported a $43 million decrease in third-quarter 2025 revenue due to revised accounts receivable collectability assessments after transitioning to a new revenue accounting system [4]. - The company also cut its 2025 EBITDA guidance by approximately 9.6%, from a range of $575 million - $615 million to $530 million - $555 million, citing persistent industry-wide cost pressures [4]. - Following these announcements, Ardent Health's stock price fell nearly 34% [4]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Ardent Health securities during the class period to seek appointment as lead plaintiff in the lawsuit, representing the interests of all class members [5].

Core Viewpoint - The Ardent Health class action lawsuit alleges that the company and its executives made misleading statements regarding financial practices and liability reserves, leading to significant stock price declines following the revelation of financial discrepancies [3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled Postiwala v. Ardent Health, Inc., and it allows purchasers of Ardent Health securities between July 18, 2024, and November 12, 2025, to seek lead plaintiff status by March 9, 2026 [1][2]. - The lawsuit claims that Ardent Health did not accurately assess the collectability of accounts receivable and misrepresented its financial position [3]. Group 2: Allegations Against Ardent Health - Allegations include that Ardent Health's accounts receivable framework allowed for inflated reporting by utilizing a 180-day cliff for uncollectible accounts [3]. - The company reportedly did not maintain sufficient professional malpractice liability insurance and had inadequate reserves to cover increasing claims due to social inflation in the New Mexico market [3]. - On November 12, 2025, Ardent Health disclosed a $43 million decrease in Q3 2025 revenue and a $57.5 million cut in EBITDA guidance, leading to a nearly 34% drop in stock price [4]. Group 3: Legal Process and Representation - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Ardent Health securities during the class period to seek lead plaintiff status, which enables them to direct the lawsuit on behalf of all class members [5]. - Investors are not required to serve as lead plaintiff to share in any potential recovery from the lawsuit [5]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [6]. - The firm has a strong track record, being ranked 1 in securing monetary relief for investors in securities class action cases [6].

Core Viewpoint - The Ardent Health class action lawsuit alleges that the company and its executives made misleading statements regarding financial practices and liability reserves, leading to significant financial losses for investors during the specified class period [3][4]. Group 1: Class Action Details - The class action lawsuit is titled Postiwala v. Ardent Health, Inc., and it allows purchasers of Ardent Health securities from July 18, 2024, to November 12, 2025, to seek lead plaintiff status by March 9, 2026 [1]. - The lawsuit claims that Ardent Health did not accurately assess the collectability of accounts receivable, which inflated its reported financial position [3]. - Allegations include that Ardent Health's accounts receivable framework allowed for delayed recognition of losses, and that the company lacked sufficient malpractice liability insurance [3]. Group 2: Financial Impact - On November 12, 2025, Ardent Health reported a $43 million decrease in third quarter revenue due to revised accounts receivable assessments and a new revenue accounting system [4]. - The company also cut its 2025 EBITDA guidance by approximately 9.6%, from a range of $575 million - $615 million to $530 million - $555 million, citing industry-wide cost pressures [4]. - Following these announcements, Ardent Health's stock price fell nearly 34% [4]. Group 3: Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Ardent Health securities during the class period to seek lead plaintiff status, which enables them to represent the interests of all class members [5]. - The lead plaintiff can choose a law firm to litigate the case, and participation as lead plaintiff does not affect an investor's ability to share in any potential recovery [5].

Core Viewpoint - The Ardent Health class action lawsuit alleges that the company and its executives made misleading statements regarding financial practices and liability reserves, leading to significant financial losses for investors during the specified class period [1][3]. Company Overview - Ardent Health, Inc. operates a network of hospitals and clinics providing various healthcare services [2]. Allegations of the Lawsuit - The lawsuit claims that Ardent Health did not rely on accurate methods for determining the collectability of accounts receivable, which allowed the company to report inflated financial figures [3]. - It is alleged that Ardent Health's accounts receivable framework utilized a "180-day cliff" for reserving accounts, delaying the recognition of losses on uncollectible accounts [3]. - The company reportedly lacked sufficient professional malpractice liability insurance and reserves to cover claims, particularly in light of increasing social inflationary pressures in the New Mexico market [3]. Financial Impact - On November 12, 2025, Ardent Health disclosed a $43 million decrease in third quarter 2025 revenue due to revised accounts receivable collectability assessments and a new revenue accounting system [4]. - The company also cut its 2025 EBITDA guidance by approximately 9.6%, from a range of $575 million - $615 million to $530 million - $555 million, citing persistent industry-wide cost pressures [4]. - Additionally, a $54 million increase in professional liability reserves was recorded due to recent settlements and ongoing litigation, reflecting broader industry trends [4]. - Following these announcements, Ardent Health's stock price fell nearly 34% [4]. Legal Process - Investors who purchased Ardent Health securities during the class period can seek to be appointed as lead plaintiff in the lawsuit, representing the interests of the class [5]. - The lead plaintiff has the authority to select a law firm for litigation and does not need to be the lead plaintiff to share in any potential recovery [5]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [6]. - The firm has a strong track record in obtaining significant recoveries in securities class action cases, including the largest recovery in history [6].